13 results - showing 1 - 10
1 2
Ordering
Details
Ratings
Journal Watch LH Leslie H. Hayes & Archana A. Patel Updated October 09, 2020 2290 0
Pediatrics
Read more Write review
 
0.0
 
0.0 (0)
Journal Watch CN Christelle Nel Updated February 16, 2020 14639 0
J Am Acad Child Adolesc Psychiatry 2019; 58(9): 853-865
Read more Write review
 
0.0
 
0.0 (0)
Journal Watch
Karen L Skjei
Karen L Skjei
Updated January 06, 2020 12315 0
Pediatric neurology 101 (2019): 18-25.
Read more Write review
 
0.0
 
0.0 (0)
Journal Watch
Karen L Skjei
Karen L Skjei
Updated December 01, 2019 31837 0
Indian Pediatrics 2019: 56, 643-646
Abstract Objective: To compare the efficacy and safety of intravenous Levetiracetam and Phenobarbitone in the treatment of neonatal seizures. Design: Open labelled, Randomized controlled trial. Setting: Level III Neonatal Intensive Care Unit (NICU). Participants: 100 neonates (0-28 days) with clinical seizures. Intervention: If seizures persisted even after correction of hypoglycemia and hypocalcemia, participants were randomized to receive either Levetiracetam (20 mg/kg) or Phenobarbitone (20 mg/kg) intravenously. The dose of same drug was repeated if seizures persisted (20 mg/kg of Levetiracetam or 10 mg/kg of Phenobarbitone) and changeover to other drug occurred if the seizures persisted even...
Read more Write review
 
0.0
 
0.0 (0)
Journal Watch
ICNA
ICNA
May 26, 2019 1397 0
Lancet 2019
Background Phenytoin is the recommended second-line intravenous anticonvulsant for treatment of paediatric convulsive status epilepticus in the UK; however, some evidence suggests that levetiracetam could be an effective and safer alternative. This trial compared the efficacy and safety of phenytoin and levetiracetam for second-line management of paediatric convulsive status epilepticus.
Read more Write review
 
0.0
 
0.0 (0)
Journal Watch
ICNA
ICNA
Updated June 11, 2018 1965 0
The Lancet May 23, 2018
Paolo Curatolo, David N Franz, John A Lawson, Zuhal Yapici, Hiroko Ikeda, Tilman Polster, Rima Nabbout, Petrus J de Vries, Dennis J Dlugos, Jenna Fan, Antonia Ridolfi, Diana Pelov, Maurizio Voi, Jacqueline A French https://doi.org/10.1016/S2352-4642(18)30099-3 Background Epilepsy occurs in 70–90% of patients with tuberous sclerosis complex. We aimed to assess the efficacy and safety of adjunctive everolimus for treatment-refractory seizures associated with tuberous sclerosis complex in paediatric patients enrolled in the EXIST-3 trial, a double-blind, placebo-controlled, randomised, phase 3 study. Methods This post-hoc analysis focused on paediatric patients...
Read more Write review
 
0.0
 
0.0 (0)
Journal Watch
ICNA
ICNA
Updated July 23, 2018 2210 0
N Engl J Med 2018; 378:1888-1897
BACKGROUND Cannabidiol has been used for treatment-resistant seizures in patients with severe early-onset epilepsy. We investigated the efficacy and safety of cannabidiol added to a regimen of conventional antiepileptic medication to treat drop seizures in patients with the Lennox–Gastaut syndrome, a severe developmental epileptic encephalopathy.  
Read more Write review
 
0.0
 
0.0 (0)
Journal Watch
ICNA
ICNA
November 23, 2017 3759 1
N Engl J Med. 2017 Nov 2;377(18):1723-1732
Findings from a randomized, double-blind, phase 3 efficacy and safety trial published in the New England Journal of Medicine suggest that infants with spinal muscular atrophy who receive nusinersen experience greater survival and motor function improvement compared with controls.
Read more Write review
 
0.0
 
0.0 (0)
Journal Watch
ICNA
ICNA
Updated July 27, 2017 3729 1
Lancet. 2017 Jul 17
Background Duchenne muscular dystrophy (DMD) is a severe, progressive, and rare neuromuscular, X-linked recessive disease. Dystrophin deficiency is the underlying cause of disease; therefore, mutation-specific therapies aimed at restoring dystrophin protein production are being explored. We aimed to assess the efficacy and safety of ataluren in ambulatory boys with nonsense mutation DMD.
Read more Write review
 
0.0
 
0.0 (0)
13 results - showing 1 - 10
1 2